The company was founded in Georgia. It was registered as a Limited Liability Company on the 4th of July 2000.
Our principal motivation is to cover human needs, developing new products to treat highly prevalent diseases that are unsatisfactorily treated by existing medicines, and which have an enormous socio-sanitary impact.
Our handpicked scientific team works on and develops effective treatments, taking care of each and every one of our products to mark a real difference in improving patient’s quality of life.
In January 2002, the construction of the "Sinuforte - Nasodren" production plant was completed with the financial support of Hartington Business,S.L. This is one of the most modern pharmaceutical plants within the territory of the former Soviet Union. The plant is equipped with state-of-the-art production lines and technological equipment manufactured by leading manufacturers in the USA and Western Europe.
The production premises were designed in accordance with GMP standards. The newest technologies are used in a constantly controlled production process. Specific objectives are set for each production stage. Effectiveness assessment criteria have been established and methods to control compliance with the regulations are applied.
Quality, innovation and excellence in research is our fundamental premise: our goal is to be a reference in the medical field. We are committed to society by developing natural products that are highly safe and effective, offering added value to existing therapies.
In 2014 Nasodren came to the Australian market. Many Australian Sufferers got new sinus infection remedy to relief their conditions.
